# Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes

> **NCT00736879** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 497 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00736879
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09-22
- **Primary completion:** 2009-12-29
- **Final completion:** 2009-12-29
- **Target enrollment:** 497 (ACTUAL)
- **Last updated:** 2017-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00736879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00736879, "Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00736879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*